UBS Maintains a Buy on Genmab (GMAB) With a DKK2,500 PT

finance.yahoo.com/news/ubs-maintains-buy-genmab-gmab-151402375.html

In This Article:
Genmab A/S (NASDAQ:GMAB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 25, UBS analyst Xian Deng maintained a Buy rating on Genmab A/S (NASDAQ:GMAB) and set a price target of DKK2,500.00.
A scientist in a lab using a microscope to develop…

This story appeared on finance.yahoo.com, 2025-07-10 15:14:02.
The Entire Business World on a Single Page. Free to Use →